Clinical Trial

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Study acronym: FOCUS 1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-16
Trial Details
NCT Number NCT07563881
Lead Sponsor Rapport Therapeutics Inc.
Conditions Focal Seizure, Epilepsy, Focal Epilepsy
Enrollment 333 participants
Start Date 2026-06-05
Primary Completion 2029-07 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-13